Oral NaV1.8 Inhibitor Designated Breakthrough Tx for Severe

The Food and Drug Administration has granted Breakthrough Therapy designation to VX-548 for the treatment of moderate to severe acute pain.

Related Keywords

, Carmen Bozic , Global Medicines Development , Drug Administration , Breakthrough Therapy , Pain Intensity Difference , Executive Vice President , Medical Affairs , Chief Medical Officer ,